EPTIFIBATIDE

Other

Brand names: Eptifibatide

Intravenous

Mechanism of Action

12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet.

Indications

new MI

or need for urgent intervention in patients undergoing PCI

including those undergoing intracoronary stenting [see Clinical Studies (14.1

14.2) ] .

Contraindications

• 4 CONTRAINDICATIONS Treatment with eptifibatide injection is contraindicated in patients with: A history of bleeding diathesis

FDA Warnings

5 WARNINGS AND PRECAUTIONS Eptifibatide can cause serious bleeding
Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs, and P2Y 12 inhibitors)

Known Side Effects

3 documented side effects by frequency

Drug Not Working

1-10%

Low Blood Pressure

1-10%

Chest Pain

0.1-1%

Community Discussions

No community discussions found for EPTIFIBATIDE yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous